Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
23.83
-0.25 (-1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arrowhead Pharma
< Previous
1
2
3
4
5
Next >
4 Analysts Assess Arrowhead Pharma: What You Need To Know
January 02, 2024
Via
Benzinga
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
December 29, 2023
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arrowhead Pharma
December 04, 2023
Via
Benzinga
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 30, 2023
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.
Via
Benzinga
Recap: Arrowhead Pharma Q4 Earnings
November 29, 2023
Via
Benzinga
Earnings Outlook For Arrowhead Pharma
November 28, 2023
Via
Benzinga
Analyst Expectations for Arrowhead Pharma's Future
September 19, 2023
Via
Benzinga
Earnings Scheduled For November 29, 2023
November 29, 2023
Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.
Via
Benzinga
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
October 31, 2023
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Analyst Ratings for Arrowhead Pharma
August 08, 2023
Via
Benzinga
Analyst Expectations for Arrowhead Pharma's Future
July 21, 2023
Via
Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Expert Ratings for Arrowhead Pharma
June 30, 2023
Via
Benzinga
Where Arrowhead Pharma Stands With Analysts
May 24, 2023
Via
Benzinga
The Latest Analyst Ratings for Arrowhead Pharma
May 03, 2023
Via
Benzinga
Is Arrowhead Pharmaceuticals a Buy Now?
April 16, 2023
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
Via
The Motley Fool
Expert Ratings for Arrowhead Pharma
April 12, 2023
Via
Benzinga
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease
June 01, 2023
Arrowhead CEO Christopher Anzalone discusses expectations for ARO-RAGE in lung disease.
Via
Investor's Business Daily
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
May 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
May 12, 2023
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
April 25, 2023
Via
Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.